Recent Finacing
Recent Raise
Atox Bio is a clinical-stage biotech in Ness Ziona and Chapel Hill developing Reltecimod (AB103), a CD28-binding peptide immunomodulator in Phase 3 for necrotizing soft-tissue infections.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors